IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v143y2024ics016885102400054x.html
   My bibliography  Save this article

Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada

Author

Listed:
  • Douglas, Conor M.W.
  • Grunebaum, Shir

Abstract

Risk sharing agreements (RSAs) and managed access agreements have emerged as tools to overcome evidentiary uncertainty and contain costs of pharmaceuticals; however, Canada has relatively little experience with these health policy instruments. This article describes one of the few examples of national RSAs. Enzyme replacement therapies (ERT) were introduced in Canada to treat Fabry disease in the early 2000s through an RSA. Based on qualitative interviews with key participating actors, this article explains how this RSA ensured continuity of treatment for patients already on ERT, and collected robust real-world evidence to secure treatment for future Fabry patients. We show the importance of partnerships, collaborations, and active patient communities in establishing RSAs, as well as the critical role of robust registries for the collection, storage, and use of that real-world data. In doing so, this paper points to reasons that explain the relative dearth of RSAs in Canada, which can be resource (both human and finance) intensive and are difficult to broker in a federalist health system. Through these findings, policy lessons are developed concerning the need for technological and governance platforms on how RSA in Canada can be more effectively supported going forward in a broader move towards “social pharmaceutical innovation”.

Suggested Citation

  • Douglas, Conor M.W. & Grunebaum, Shir, 2024. "Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada," Health Policy, Elsevier, vol. 143(C).
  • Handle: RePEc:eee:hepoli:v:143:y:2024:i:c:s016885102400054x
    DOI: 10.1016/j.healthpol.2024.105044
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S016885102400054X
    Download Restriction: Full text for ScienceDirect subscribers only

    File URL: https://libkey.io/10.1016/j.healthpol.2024.105044?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Russo, Pierluigi & Carletto, Angelica & Németh, Gergely & Habl, Claudia, 2021. "Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey," Health Policy, Elsevier, vol. 125(9), pages 1140-1145.
    2. Wranik, Wiesława Dominika & Gambold, Liesl & Peacock, Stuart, 2021. "Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland," Health Policy, Elsevier, vol. 125(3), pages 307-319.
    3. Palm, Willy & Webb, Erin & Hernández-Quevedo, Cristina & Scarpetti, Giada & Lessof, Suszy & Siciliani, Luigi & van Ginneken, Ewout, 2021. "Gaps in coverage and access in the European Union," Health Policy, Elsevier, vol. 125(3), pages 341-350.
    4. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green, 2020. "Who should be given priority for public funding?," Health Policy, Elsevier, vol. 124(10), pages 1108-1114.
    5. Morgan, Steven G. & Daw, Jamie R. & Greyson, Devon & Shnier, Adrienne & Holbrook, Anne & Lexchin, Joel, 2020. "Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature," Health Policy, Elsevier, vol. 124(3), pages 231-238.
    6. Eren Vural, Ipek & Herder, Matthew & Graham, Janice E., 2021. "From sandbox to pandemic: Agile reform of Canadian drug regulation," Health Policy, Elsevier, vol. 125(9), pages 1115-1120.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Elena Puerto-Casasasnovas & Jorge Galiana-Richart & María Paola Mastrantonio-Ramos & Francisco López-Muñoz & Alfredo Rocafort-Nicolau, 2023. "Direct and Indirect Management Models in Public Health in the Framework of Mental Health," IJERPH, MDPI, vol. 20(3), pages 1-11, January.
    2. Williams, Iestyn & Kapiriri, Lydia & Vélez, Claudia-Marcela & Aguilera, Bernardo & Danis, Marion & Essue, Beverley & Goold, Susan & Noorulhuda, Mariam & Nouvet, Elysee & Razavi, Donya & Sandman, Lars, 2024. "How did European countries set health priorities in response to the COVID-19 threat? A comparative document analysis of 24 pandemic preparedness plans across the EURO region," Health Policy, Elsevier, vol. 141(C).
    3. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green & Hong, Jihyung, 2023. "Public preferences in healthcare resource allocation: A discrete choice experiment in South Korea," Health Policy, Elsevier, vol. 138(C).
    4. Kelleher, Dan & Doherty, Edel & O'Neill, Ciaran, 2022. "Examining the transnational preventive healthcare utilisation of a group of Eastern European migrants living full-time in another European state," Health Policy, Elsevier, vol. 126(4), pages 318-324.
    5. Roxana Margan & Madalin-Marius Margan & Corneluta Fira-Mladinescu & Salomeia Putnoky & Ioana Tuta-Sas & Radu Bagiu & Zoran Laurentiu Popa & Elena Bernad & Ioana Mihaela Ciuca & Felix Bratosin & Oana C, 2022. "Impact of Stress and Financials on Romanian Infertile Women Accessing Assisted Reproductive Treatment," IJERPH, MDPI, vol. 19(6), pages 1-10, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:143:y:2024:i:c:s016885102400054x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.